X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dishman Pharma with Merck Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs MERCK LTD - Comparison Results

DISHMAN PHARMA    Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

MERCK LTD 
   Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA MERCK LTD DISHMAN PHARMA/
MERCK LTD
 
P/E (TTM) x 25.1 44.3 56.6% View Chart
P/BV x 3.3 6.5 51.8% View Chart
Dividend Yield % 0.7 0.5 126.4%  

Financials

 DISHMAN PHARMA   MERCK LTD
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
MERCK LTD
Dec-17
DISHMAN PHARMA/
MERCK LTD
5-Yr Chart
Click to enlarge
High Rs3741,358 27.6%   
Low Rs129933 13.8%   
Sales per share (Unadj.) Rs197.8665.0 29.7%  
Earnings per share (Unadj.) Rs21.256.6 37.5%  
Cash flow per share (Unadj.) Rs34.772.5 47.9%  
Dividends per share (Unadj.) Rs2.0015.00 13.3%  
Dividend yield (eoy) %0.81.3 60.7%  
Book value per share (Unadj.) Rs179.9441.7 40.7%  
Shares outstanding (eoy) m80.6916.60 486.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.31.7 73.9%   
Avg P/E ratio x11.920.2 58.6%  
P/CF ratio (eoy) x7.215.8 45.9%  
Price / Book Value ratio x1.42.6 54.0%  
Dividend payout %9.426.5 35.6%   
Avg Mkt Cap Rs m20,30619,011 106.8%   
No. of employees `0000.81.5 53.7%   
Total wages/salary Rs m5,3551,696 315.7%   
Avg. sales/employee Rs Th19,252.77,150.0 269.3%   
Avg. wages/employee Rs Th6,459.51,098.7 587.9%   
Avg. net profit/employee Rs Th2,064.1608.2 339.4%   
INCOME DATA
Net Sales Rs m15,96111,040 144.6%  
Other income Rs m265240 110.7%   
Total revenues Rs m16,22611,279 143.9%   
Gross profit Rs m4,1031,376 298.2%  
Depreciation Rs m1,091264 413.1%   
Interest Rs m9440-   
Profit before tax Rs m2,3341,352 172.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m10-   
Extraordinary Inc (Exp) Rs m0170 0.0%   
Tax Rs m624583 107.0%   
Profit after tax Rs m1,711939 182.2%  
Gross profit margin %25.712.5 206.2%  
Effective tax rate %26.743.1 62.0%   
Net profit margin %10.78.5 126.0%  
BALANCE SHEET DATA
Current assets Rs m11,0187,523 146.5%   
Current liabilities Rs m9,5172,253 422.5%   
Net working cap to sales %9.447.7 19.7%  
Current ratio x1.23.3 34.7%  
Inventory Days Days11052 211.8%  
Debtors Days Days3541 85.9%  
Net fixed assets Rs m16,3041,240 1,315.2%   
Share capital Rs m161166 97.2%   
"Free" reserves Rs m12,9077,167 180.1%   
Net worth Rs m14,5167,333 198.0%   
Long term debt Rs m4,1890-   
Total assets Rs m29,8059,912 300.7%  
Interest coverage x3.5NM-  
Debt to equity ratio x0.30-  
Sales to assets ratio x0.51.1 48.1%   
Return on assets %8.99.5 94.0%  
Return on equity %11.812.8 92.0%  
Return on capital %17.520.8 84.5%  
Exports to sales %24.80-   
Imports to sales %3.70-   
Exports (fob) Rs m3,956NA-   
Imports (cif) Rs m596NA-   
Fx inflow Rs m4,9521,015 488.0%   
Fx outflow Rs m6973,043 22.9%   
Net fx Rs m4,255-2,028 -209.8%   
CASH FLOW
From Operations Rs m2,786537 519.3%  
From Investments Rs m-1,529-476 321.0%  
From Financial Activity Rs m-941-220 428.2%  
Net Cashflow Rs m316-160 -198.4%  

Share Holding

Indian Promoters % 61.4 0.0 -  
Foreign collaborators % 0.0 51.8 -  
Indian inst/Mut Fund % 3.7 18.2 20.3%  
FIIs % 12.7 1.0 1,270.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.1 29.1 75.9%  
Shareholders   46,261 28,591 161.8%  
Pledged promoter(s) holding % 35.8 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   TTK HEALTHCARE  ALEMBIC LTD  CIPLA  ELDER PHARMA  SUVEN LIFE  

Compare DISHMAN PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 150 Points Higher; Banking Stocks Witness Buying(Closing)

Indian share markets continued their momentum and ended the day on a positive note. Gains were largely seen in the banking sector, consumer durables sector and realty sector.

Related Views on News

MERCK LTD Announces Quarterly Results (2QFY19); Net Profit Up 29.8% (Quarterly Result Update)

Nov 5, 2018 | Updated on Nov 5, 2018

For the quarter ended September 2018, MERCK LTD has posted a net profit of Rs 411 m (up 29.8% YoY). Sales on the other hand came in at Rs 2 bn (down 27.7% YoY). Read on for a complete analysis of MERCK LTD's quarterly results.

MERCK LTD Announces Quarterly Results (1QFY19); Net Profit Up 63.1% (Quarterly Result Update)

Aug 8, 2018 | Updated on Aug 8, 2018

For the quarter ended June 2018, MERCK LTD has posted a net profit of Rs 328 m (up 63.1% YoY). Sales on the other hand came in at Rs 2 bn (down 17.1% YoY). Read on for a complete analysis of MERCK LTD's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My Top 7 Stocks to Buy Now(The 5 Minute Wrapup)

Nov 30, 2018

Of all the stocks that you could buy in this market, I've picked the seven best safe stocks that offer the ideal combination of safety and profit.

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

Safety Beats Growth in 2018(Chart Of The Day)

Nov 30, 2018

With the markets turning up, these are my top 7 stock picks.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

DSP Mutual Fund's Sale of DHFL Bonds: Here's What You Need to Know(Outside View)

Dec 5, 2018

PersonalFN explains the probable reason as to why the capital market regulator has initiated DSP Mutual Fund's bond sale that caused DHFL stock to crash.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA - PANACEA BIOTECH COMPARISON

COMPARE DISHMAN PHARMA WITH

MARKET STATS